{
    "clinical_study": {
        "@rank": "93965", 
        "arm_group": [
            {
                "arm_group_label": "SPI-1620 & Docetaxel", 
                "arm_group_type": "Experimental", 
                "description": "Single Arm and Randomized Part:\nSPI-1620: 11\u03bcg/m2 Docetaxel: 75 mg/m2"
            }, 
            {
                "arm_group_label": "Docetaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Randomized Part only Docetaxel: 75 mg/m2 on Day 1 in 3-week cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate and compare the objective response rate of SPI-1620\n      administered in combination with docetaxel in patients with NSCLC and to determine the\n      safety of SPI-1620 when administered in combination with docetaxel."
        }, 
        "brief_title": "Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a two part study. In Single Arm Part, patients will receive 11 \u03bcg/m2 of\n      SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until\n      progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm\n      Part. If 6 or more responses (CR/PR) are observed in this group then the Randomized Part\n      will be initiated.\n\n      In the Randomized Part approximately 200 patients (100 per arm) will be randomized to\n      receive SPI-1620 plus docetaxel or docetaxel alone.\n\n      In the experimental arm, patients will receive 11 \u03bcg/m2 of SPI-1620 IV followed by docetaxel\n      75 mg/m2 IV administered in 3-week cycles until progression or intolerable toxicity. In the\n      control arm, patients will receive 75 mg/m2 docetaxel in 3-week cycles until progression or\n      intolerable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed locally advanced or metastatic NSCLC that\n             has failed one prior platinum-containing chemotherapy\n\n          -  Measurable disease as per RECIST v. 1.1\n\n          -  ECOG performance status of 0, 1 or 2\n\n          -  Adequate bone marrow, liver and renal function\n\n        Exclusion Criteria:\n\n          -  More than one prior chemotherapy regimen for metastatic NSCLC\n\n          -  Known, uncontrolled CNS metastases\n\n          -  Significant circulatory disorders in the past 6 mo.\n\n          -  Concomitant treatment with phosphodiesterase inhibitors\n\n          -  Uncontrolled orthostatic hypotension, asthma or COPD"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "227", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741155", 
            "org_study_id": "SPI-1620-12-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "SPI-1620 & Docetaxel", 
                "description": "Single Arm & Randomized Part:\nOn Day 1, the patient will receive standard docetaxel premedication followed by SPI-1620 11 \u03bcg/m2 administered intravenously over one minute. Patients will receive docetaxel 10 (\u00b12) minutes following the infusion of SPI-1620. Docetaxel dose is 75 mg/m2 infusion. Patients will continue to receive SPI-1620 plus docetaxel once every 3 weeks until disease progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm Part. If 6 or more responses are observed in this group then the Randomized Part will be initiated. About 100 patient in the experimental arm will receive SPI-1620 & Docetaxel", 
                "intervention_name": "SPI-1620 & Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Docetaxel (Taxotere)"
            }, 
            {
                "arm_group_label": "Docetaxel", 
                "description": "Randomized Part-Control Arm (100 patient):\nOn Day 1 the patient will receive standard docetaxel premedication followed by docetaxel 75 mg/m2 by infusion over 1 hour. Patients will continue to receive docetaxel once every 3 weeks until disease progression or intolerable toxicity.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology PLLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "The Center for Cancer and Blood Disorders"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }, 
                    "name": "Virginia Cancer Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy", 
        "overall_official": {
            "affiliation": "Spectrum Pharmaceuticals, Inc", 
            "last_name": "Mi Rim Choi, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC", 
            "measure": "Objective Response Rate(ORR) of SPI-1620", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741155"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "only in Randomized Part.", 
                "measure": "Duration of Response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "only in Randomized Part", 
                "measure": "Progression-free survival(PFS)", 
                "safety_issue": "No", 
                "time_frame": "2 years from the start of study treatment"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "2 years from the start of study treatment"
            }, 
            {
                "description": "Periodic physical examinations with vital sign monitoring, safety laboratories and monitoring of adverse events will be performed.", 
                "measure": "Safety of SPI-1620", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Spectrum Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spectrum Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}